Patent · US Expired

Recombinant blood clotting factors

US7572619B2 · kind B2 · utility

22Cited by

2References

44Claims

0Family size

Assignee

Octagene GmbH · DE

Inventors

Charlotte Hauser · Thuwal, SA
Andrea Hörster · Ebersberg, DE
Carola Schröder · Munich, DE
Michael Lehnerer · Munich, DE

Key dates

Filing date	Mar 21, 2001
Grant date	Aug 11, 2009
Priority date	—
Expiry date	Mar 21, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K48/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX. An immortalized human cell line can be used to stably express viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins. The invention further relates to an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins, and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.